Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Accumulated Expenses data on file, last reported at $25.5 million in Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 14.59% year-over-year to $25.5 million in Q4 2025; TTM through Dec 2025 was $25.5 million, a 14.59% decrease from a year earlier, with the FY2025 full-year figure at $25.5 million, down 14.59% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $25.5 million, down from $27.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for INBX reached as high as $43.3 million in Q4 2023 and fell as low as $23.9 million in Q2 2024.
• Historically, Accumulated Expenses has averaged $30.1 million across 3 years, with a median of $29.2 million in 2024.
• Across the five-year window, Accumulated Expenses sank 30.96% in 2024 and climbed 19.35% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $43.3 million in 2023, then sank by 30.96% to $29.9 million in 2024, then dropped by 14.59% to $25.5 million in 2025.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $25.5 million in Q4 2025, $27.0 million in Q3 2025, and $28.5 million in Q2 2025.